ClinicalTrials.gg
CompletedNCT01037062Updated Jan 31, 2011

An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection

A Phase 2 interventional study of Entecavir in Chronic Hepatitis B, sponsored by Bristol-Myers Squibb. Completed at 48 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-01-31.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
13th of 61
282 · median 109
Started
2003
with 2 others
Phase 2
9 of 64
1 open now
Registered
27th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 13th largest by enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2003, is one of 9 in phase 2, and was the 27th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

To provide open-label entecavir to subjects who have completed previous blinded entecavir trials in Japan and are assessed by the investigator as likely to benefit from additional anti-hepatitis B therapy

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who completed a previous entecavir Phase II studies (AI463047, 052 or 053);
  • ≤ 10 x ;
  • Subjects must have well-compensated liver disease according to ALL of the following criteria;

    1. ≤ 3 seconds prolonged compared to control value or INR ≤ 1.5
    2. Serum albumin ≥ 3 g/dL (≥ 30 g/L)
    3. Serum ≤ 2.5 mg/dL (≤ 42.75 μmol/L)

Exclusion criteria

Exclusion Criteria:

  • Sex and Reproductive Status Exceptions
  • Target Disease Exceptions
  • Medical History and Concurrent Diseases
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    Entecavir

    Drug: Entecavir

Interventions

  • Tablet, P.O. 0.5, 1 mg, once daily

    Also known as: Baraclude, BMS-200475

06

What researchers measure

Primary outcomes

  1. To provide open-label entecavir to subjects who have completed previous blinded entecavir trials in Japan and are assessed by the investigator as likely to benefit from additional anti-hepatitis B therapy

    Time frame: 24 weeks

Secondary outcomes

  1. Incidence of clinical adverse events and discontinuations due to adverse events of entecavir for each cohort

    Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 post dosing

  2. Incidence of laboratory abnormalities of of entecavir for each cohort

    Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 post dosing

  3. Proportion of subjects HBeAg-positive at baseline who have loss of HBeAg from serum

    Time frame: Day 1, Week 12, Week 24 and every subsequent 24 week during dosing

  4. Proportion of subjects HBeAg-positive at baseline who achieve seroconversion (loss of HBeAg and appearance of HBeAb)

    Time frame: Day 1, Week 12, Week 24 and every subsequent 24 week during dosing

  5. Proportion of subjects with abnormal ALT at baseline who achieve normalization of serum ALT at Week 48

    Time frame: Day 1, Week 48

  6. Proportion of subjects who achieve HBV DNA levels by PCR assay less than the limit of quantification (LOQ)

    Time frame: Day 1, Week 12, 24, and subsequent 24 week during dosing

  7. Proportion of subjects positive for HBeAg at baseline who achieve HBV DNA levels by PCR assay less than LOQ, normal serum ALT, and seroconversion

    Time frame: Week 8, 16, 24 post dosing

  8. Proportion of subjects negative for HBeAg at baseline who achieve HBV DNA levels by PCR assay less than LOQ and normal ALT and remain negative for HBeAg

    Time frame: Day 1, Week 12, Week 24 and every subsequent 24 weeks during dosing

  9. Proportion of subjects who achieved Complete Response during therapy, who have sustained Complete Response for 24 weeks after stopping drug

    Time frame: 24 Week post dosing

  10. Proportion of subjects with histological improvement in the liver at Wks 48 & 96 [improvement in necroinflammatory score and no worsening of fibrosis at Wks 48 & 96 liver biopsy compared to baseline & to baseline in previous study]

    Time frame: Week 48, 96

  11. NChanges in liver histology as assessed by the New Inuyama Classification for histological assessment of chronic hepatitis

    Time frame: Week 48 & Week 96

  12. Incidence of genotypic changes in HBV DNA polymerase conferring resistance to entecavir in subjects with confirmed ≥1 log10 increase in HBV DNA from nadir on treatment

    Time frame: Week 2, 4, ± days, Week 8 every 4 weeks ± 7 days

07

Study locations

48 sites
  • Local Institution
    Aichi-Gun, Aichi 480-1195, Japan
  • Local Institution
    Nagoya-Shi, Aichi 457-0866, Japan
  • Local Institution
    Nagoya-Shi, Aichi 467-8602, Japan
  • Local Institution
    Nagoya, Aichi 466-8550, Japan
  • Local Institution
    Chiba-Shi, Chiba, Japan
  • Local Institution
    Onsen-Gun, Ehime 791-0204, Japan
  • Local Institution
    Fukuoka-Shi, Fukuoka 814-0180, Japan
  • Local Institution
    Kurume, Fukuoka, Japan
  • Local Institution
    Gifu-Shi, Gifu 500-8513, Japan
  • Local Institution
    Ogaki-Shi, Gifu 503-8502, Japan
  • Local Institution
    Fukuyama-Shi, Hiroshima 721-0971, Japan
  • Local Institution
    Hiroshima City, Hiroshima 734-0037, Japan
  • Local Institution
    Hiroshima-Shi, Hiroshima 730-8518, Japan
  • Local Institution
    Asahikawa-Shi, Hokkaido 070-0054, Japan
  • Local Institution
    Sapporo-Shi, Hokkaido 006-0813, Japan
  • Local Institution
    Sapporo-Shi, Hokkaido 060-0033, Japan
  • Local Institution
    Akashi-Shi, Hyogo 673-0848, Japan
  • Local Institution
    Morioka-Shi, Iwate 020-8505, Japan
  • Local Institution
    Mitoyo-Gun, Kagawa 769-1601, Japan
  • Local Institution
    Takamatsu-City, Kagawa, Japan
  • Local Institution
    Kumamoto-Shi, Kumamoto 860-8556, Japan
  • Local Institution
    Sendai, Miyagi, Japan
  • Local Institution
    Miyazaki-Gun, Miyazaki 889-1692, Japan
  • Local Institution
    Matsumoto City, Nagano 390-0802, Japan
  • Local Institution
    Nagasaki City, Nagasaki, Japan
  • Local Institution
    Omura-Shi, Nagasaki 856-0000, Japan
  • Local Institution
    Oita-Gun, Oita 879-5503, Japan
  • Local Institution
    Kurashiki-Shi, Okayama 710-8602, Japan
  • Local Institution
    Okayama-Shi, Okayama 700-0082, Japan
  • Local Institution
    Okayama-Shi, Okayama 700-8505, Japan
  • Local Institution
    Okayama-Shi, Okayama 700-8511, Japan
  • Local Institution
    Tsuyama-Shi, Okayama 708-0841, Japan
  • Local Institution
    Kawachinagano-Shi, Osaka 86-0008, Japan
  • Local Institution
    Osaka-Shi, Osaka 553-0003, Japan
  • Local Institution
    Sakai-Shi, Osaka 591-8025, Japan
  • Local Institution
    Suita-Shi, Osaka, Japan
  • Local Institution
    Iruma-Gun, Saitama 350-0495, Japan
  • Local Institution
    Minato-Ku, Tokyo 105-0001, Japan
  • Local Institution
    Musashino-Shi, Tokyo 180-0023, Japan
  • Local Institution
    Shinjuku-Ku, Tokyo 160-8582, Japan
  • Local Institution
    Shinjuku-Ku, Tokyo 162-8655, Japan
  • Local Institution
    Shinjuku-Ku, Tokyo 162-8666, Japan
  • Local Institution
    Ube-Shi, Yamaguchi 755-0067, Japan
  • Local Institution
    Nakakoma-Gun, Yamanashi 409-3821, Japan
  • Local Institution
    Kyoto, Japan
  • Local Institution
    Niigata, Japan
  • Local Institution
    Osaka, Japan
  • Local Institution
    Tokyo, 173-8610, Japan
08

References and documents

Publications

  • Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol. 2010 Jun;52(6):791-9. doi: 10.1016/j.jhep.2009.12.036. Epub 2010 Mar 24. PubMed 20409606 ↗
  • Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, Ishikawa H, Masaki N, Seriu T, Omata M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010 Feb 6;4(1):414-22. doi: 10.1007/s12072-009-9162-x. Erratum In: Hepatol Int. 2010;4(4):789-90. PubMed 20305760 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2009
First posted
Dec 21, 2009
Start
Dec 2003
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results delay requested
Jan 29, 2010
Last update
Jan 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01037062
First posted
Dec 21, 2009
Start date
Dec 2003
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Jan 31, 2011

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion